SCHEMBL3963652

SCHEMBL3963652

CCOc1nc(N(Cc2ccccc2)Cc2ccccc2)ccc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.38
TSHR P16473 2/20 0.36
NR1H2 P55055 2/20 0.36
NR1H3 Q13133 2/20 0.36
HRH4 Q9H3N8 1/20 0.35
CHRM2 P08172 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
DRD1 P21728 1/20 0.35
SLC6A2 P23975 1/20 0.35
HTR2A P28223 1/20 0.35
SLC6A4 P31645 1/20 0.35
ADRA1A P35348 1/20 0.35
HRH1 P35367 1/20 0.35
OPRK1 P41145 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KCNH2 Q12809 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
CETP P11597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2031466 0.86 CTSK (0.37) CTSKTSHRNR1H2NR1H3CHRM2
SCHEMBL1862955 0.86 LMNA (0.40) TSHRCHRM2ADRA2ADRD1HTR2A
SCHEMBL31711364 0.83 CETP (0.36) CTSKTSHRNR1H2NR1H3ADRA2A
SCHEMBL14108957 0.79 CYP2C19 (0.40) CTSKTSHRNR1H2NR1H3CHRM2
SCHEMBL31715974 0.76 XPO1 (0.40) CTSKNR1H2NR1H3PTGDR2KDM4E
SCHEMBL2974934 0.76 XPO1 (0.40) CTSKNR1H2NR1H3PTGDR2KDM4E
SCHEMBL17707980 0.70 NPC1 (0.41) TSHRKDM4EHPGDL3MBTL1HSD17B10
SCHEMBL1858748 0.69 CFTR (0.41) KDM4ELMNAALDH1A1L3MBTL1
SCHEMBL18833366 0.69 CDK1 (0.38) CTSKKDM4ESMN1; SMN2HPGD
Ammonia Solution, Strong SCHEMBL3968047 0.68 NR1H2 (0.37) NR1H2NR1H3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841430-A4 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORP (US) 2009-07-29 EP disclosed
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues NEUROGEN CORPORATION (US) 2008-07-24 US disclosed
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues NEUROGEN CORPORATION (US) 2008-07-24 US disclosed
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues NEUROGEN CORPORATION (US) 2008-07-24 US disclosed
EP-1841430-A2 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2007-10-10 EP disclosed
WO-2006081388-A2 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues PIGS, HRH4, GPR68 CTSK 2078/4885TSHR 125/4885NR1H2 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.